Expertise in
26
conditions

Dr. Michael A. Morse

Interventional Cardiology | Cardiology
Saint Thomas Medical Partners
100 Physicians Way, Suite 330, 
Lebanon, TN 
Accepting New Patients
Offers Telehealth
Expertise in
26
conditions
Saint Thomas Medical Partners
100 Physicians Way, Suite 330, 
Lebanon, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Morse is an Interventional Cardiologist and a Cardiologist in Lebanon, Tennessee. Dr. Morse is highly rated in 26 conditions, according to our data. His top areas of expertise are Mitral Valve Regurgitation, Aortic Valve Stenosis, Necrosis, Heart Valve Repair, and Aortic Valve Replacement. Dr. Morse is currently accepting new patients.

His clinical research consists of co-authoring 246 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in IL
Hospital Affiliations
Saint Thomas Rutherford Hospital
Ascension Saint Thomas Hospital
West Tennessee Healthcare Henry County Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
View 1 Less Insurance Carrier -

Locations

SAINT THOMAS MEDICAL PARTNERS
100 Physicians Way, Suite 330, Lebanon, TN 37090
Other Locations
SAINT THOMAS MEDICAL PARTNERS
4230 Harding Pike, Suite 535, Nashville, TN 37205
SAINT THOMAS MEDICAL PARTNERS
300 20th Ave N, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2025
Intervention Type: Drug, Device
Study Phase: Not Applicable
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Device, Drug
Study Phase: Not Applicable
A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
Enrollment Status: Terminated
Publish Date: May 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR
ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR
Enrollment Status: Active_not_recruiting
Publish Date: April 27, 2025
Intervention Type: Device
Study Phase: Not Applicable
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: ATP-128, BI-754091
Study Phase: Phase 1
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Enrollment Status: Terminated
Publish Date: June 23, 2017
Intervention Type: Device
Study Phase: Phase 3
View 8 Less Clinical Trials

245 Total Publications

Privacy violations in election results.
Privacy violations in election results.
Journal: Science advances
Published: March 12, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Kashish Goel
Interventional Cardiology | Cardiology
Expertise in
29
conditions
Dr. Kashish Goel
Interventional Cardiology | Cardiology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (26.8 mi)
615-322-3000
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Kashish Goel is an Interventional Cardiologist and a Cardiologist in Nashville, Tennessee. Dr. Goel is highly rated in 29 conditions, according to our data. His top areas of expertise are Mitral Valve Regurgitation, Aortic Valve Stenosis, Sengers Syndrome, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Goel is currently accepting new patients.

Expertise in
14
conditions
Dr. Italo O. Biaggioni
Cardiology
Expertise in
14
conditions
Dr. Italo O. Biaggioni
Cardiology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (26.8 mi)
615-322-3000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Italo Biaggioni is a Cardiologist in Nashville, Tennessee. Dr. Biaggioni is highly rated in 14 conditions, according to our data. His top areas of expertise are Orthostatic Hypotension, Low Blood Pressure, Familial Dysautonomia, and Postural Orthostatic Tachycardia Syndrome (POTS). Dr. Biaggioni is currently accepting new patients.

Expertise in
12
conditions
Dr. Satish R. Raj
Cardiology | Cardiac Electrophysiology
Expertise in
12
conditions
Dr. Satish R. Raj
Cardiology | Cardiac Electrophysiology
Aa3228 Medical Ctr N, 1161 21st Avenue South, 
Nashville, TN 
 (26.8 mi)
615-322-3000
Languages Spoken:
English

Satish Raj is a Cardiologist and a Cardiac Electrophysiologist in Nashville, Tennessee. Dr. Raj is highly rated in 12 conditions, according to our data. His top areas of expertise are Familial Dysautonomia, Postural Orthostatic Tachycardia Syndrome (POTS), Low Blood Pressure, Orthostatic Hypotension, and Pacemaker Implantation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morse's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile